{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T10:42:04Z","timestamp":1794998524576,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["GrantNo.IP.2007.32011.011"],"award-info":[{"award-number":["GrantNo.IP.2007.32011.011"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Global Alliance for TB Drug Development"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12916-016-0565-y","type":"journal-article","created":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T12:10:06Z","timestamp":1454587806000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-7024","authenticated-orcid":false,"given":"Patrick P. J.","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl M.","family":"Mendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divan A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Crook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Nunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Diacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen H.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,4]]},"reference":[{"issue":"17","key":"565_CR1","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","volume":"371","author":"SH Gillespie","year":"2014","unstructured":"Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577\u201387.","journal-title":"N Engl J Med"},{"issue":"17","key":"565_CR2","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","volume":"371","author":"A Jindani","year":"2014","unstructured":"Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371(17):1599\u2013608.","journal-title":"N Engl J Med"},{"issue":"17","key":"565_CR3","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","volume":"371","author":"CS Merle","year":"2014","unstructured":"Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17):1588\u201398.","journal-title":"N Engl J Med"},{"key":"565_CR4","volume-title":"Global tuberculosis report 2014","author":"World Health Organization (WHO)","year":"2014","unstructured":"World Health Organization (WHO). Global tuberculosis report 2014. Geneva: WHO; 2014."},{"issue":"9979","key":"565_CR5","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","volume":"385","author":"M Uplekar","year":"2015","unstructured":"Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO\u2019s new end TB strategy. Lancet. 2015;385(9979):1799\u2013801.","journal-title":"Lancet"},{"issue":"1","key":"565_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/civ195","volume":"61","author":"DJ Sloan","year":"2015","unstructured":"Sloan DJ, Mwandumba HC, Garton NJ, Khoo SH, Butterworth AE, Allain TJ, et al. Pharmacodynamic modeling of bacillary elimination rates and detection of bacterial lipid bodies in sputum to predict and understand outcomes in treatment of pulmonary tuberculosis. Clin Infect Dis. 2015;61(1):1\u20138.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"565_CR7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1473-3099(10)70071-2","volume":"10","author":"DJ Horne","year":"2010","unstructured":"Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis. 2010;10(6):387\u201394.","journal-title":"Lancet Infect Dis"},{"key":"565_CR8","first-page":"3","volume-title":"Clinical measurement in drug evaluation","author":"RJ Temple","year":"1995","unstructured":"Temple RJ. A regulatory authority\u2019s opinion about surrogate endpoints. In: Nimmo WS, Tucker GT, editors. Clinical measurement in drug evaluation. New York: Wiley; 1995. p. 3\u201322."},{"issue":"5","key":"565_CR9","doi-asserted-by":"crossref","first-page":"e63840","DOI":"10.1371\/journal.pone.0063840","volume":"8","author":"PPJ Phillips","year":"2013","unstructured":"Phillips PPJ, Fielding K, Nunn AJ. An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One. 2013;8(5):e63840.","journal-title":"PLoS One"},{"issue":"2","key":"565_CR10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1473-3099(09)70256-7","volume":"10","author":"PP Phillips","year":"2010","unstructured":"Phillips PP, Davies GR, Mitchison DA. Biomarkers for tuberculosis disease activity, cure, and relapse. [Correspondence]. Lancet Infect Dis. 2010;10(2):69\u201370. author reply 70\u201361.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"565_CR11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1473-3099(10)70003-7","volume":"10","author":"RS Wallis","year":"2010","unstructured":"Wallis RS, Wang C, Doherty TM, Onyebujoh P, Vahedi M, Laang H, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis. 2010;10(2):68\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"565_CR12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","volume":"371","author":"AH Diacon","year":"2014","unstructured":"Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723\u201332.","journal-title":"N Engl J Med"},{"issue":"2","key":"565_CR13","first-page":"128","volume":"12","author":"R Rustomjee","year":"2008","unstructured":"Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2008;12(2):128\u201338.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9979","key":"565_CR14","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/S0140-6736(14)62002-X","volume":"385","author":"R Dawson","year":"2015","unstructured":"Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8\u00a0weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015;385(9979):1738\u201347.","journal-title":"Lancet"},{"issue":"8","key":"565_CR15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMp1314385","volume":"371","author":"E Cox","year":"2014","unstructured":"Cox E, Laessig K. FDA approval of bedaquiline \u2014 the benefit-risk balance for drug-resistant tuberculosis. N Engl J Med. 2014;371(8):689\u201391.","journal-title":"N Engl J Med"},{"issue":"10 Suppl 2","key":"565_CR16","first-page":"S231","volume":"3","author":"W Fox","year":"1999","unstructured":"Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10 Suppl 2):S231\u201379.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"565_CR17","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1080\/10543406.2014.971170","volume":"25","author":"DA Burger","year":"2015","unstructured":"Burger DA, Schall R. A Bayesian nonlinear mixed-effects regression model for the characterization of early bactericidal activity of tuberculosis drugs. J Biopharm Stat. 2015;25(6):1247\u201371.","journal-title":"J Biopharm Stat"},{"issue":"1","key":"565_CR18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/sim.4780040112","volume":"4","author":"J Cuzick","year":"1985","unstructured":"Cuzick J. A Wilcoxon-type test for trend. Stat Med. 1985;4(1):87\u201390.","journal-title":"Stat Med"},{"issue":"3","key":"565_CR19","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2307\/2986270","volume":"43","author":"P Royston","year":"1994","unstructured":"Royston P, Altman DG. Regression using fractional polynomials of continuous covariates - parsimonious parametric modeling. Appl Stat. 1994;43(3):429\u201367.","journal-title":"Appl Stat"},{"issue":"5","key":"565_CR20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/1740774507083434","volume":"4","author":"DP MacKinnon","year":"2007","unstructured":"MacKinnon DP, Lockwood CM, Brown CH, Wang W, Hoffman JM. The intermediate endpoint effect in logistic and probit regression. Clin Trials. 2007;4(5):499\u2013513.","journal-title":"Clin Trials"},{"issue":"265","key":"565_CR21","doi-asserted-by":"crossref","first-page":"265ra166","DOI":"10.1126\/scitranslmed.3009501","volume":"6","author":"RY Chen","year":"2014","unstructured":"Chen RY, Dodd LE, Lee M, Paripati P, Hammoud DA, Mountz JM, et al. PET\/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci Transl Med. 2014;6(265):265ra166.","journal-title":"Sci Transl Med"},{"issue":"6","key":"565_CR22","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.tube.2015.08.001","volume":"95","author":"XA Kayigire","year":"2015","unstructured":"Kayigire XA, Friedrich SO, van der Merwe L, Donald PR, Diacon AH. Simultaneous staining of sputum smears for acid-fast and lipid-containing Myobacterium tuberculosis can enhance the clinical evaluation of antituberculosis treatments. Tuberculosis (Edinb). 2015;95(6):770\u20139.","journal-title":"Tuberculosis (Edinb)"},{"issue":"10","key":"565_CR23","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/jac\/dkv178","volume":"70","author":"RJ Hammond","year":"2015","unstructured":"Hammond RJ, Baron VO, Oravcova K, Lipworth S, Gillespie SH. Phenotypic resistance in mycobacteria: is it because I am old or fat that I resist you? J Antimicrob Chemother. 2015;70(10):2823\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"565_CR24","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/infdis\/jiv149","volume":"212","author":"ND Walter","year":"2015","unstructured":"Walter ND, Dolganov GM, Garcia BJ, Worodria W, Andama A, Musisi E, et al. Transcriptional adaptation of drug-tolerant Mycobacterium tuberculosis during treatment of human tuberculosis. J Infect Dis. 2015;212(6):990\u20138.","journal-title":"J Infect Dis"},{"issue":"9","key":"565_CR25","first-page":"796","volume":"4","author":"DA Mitchison","year":"2000","unstructured":"Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis. 2000;4(9):796\u2013806.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"565_CR26","doi-asserted-by":"crossref","first-page":"e71116","DOI":"10.1371\/journal.pone.0071116","volume":"8","author":"RS Wallis","year":"2013","unstructured":"Wallis RS, Wang C, Meyer D, Thomas N. Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model. PLoS One. 2013;8(8):e71116.","journal-title":"PLoS One"},{"issue":"4","key":"565_CR27","doi-asserted-by":"crossref","first-page":"e0125403","DOI":"10.1371\/journal.pone.0125403","volume":"10","author":"RS Wallis","year":"2015","unstructured":"Wallis RS, Peppard T, Hermann D. Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update. PLoS One. 2015;10(4):e0125403.","journal-title":"PLoS One"},{"issue":"9670","key":"565_CR28","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(09)60333-0","volume":"373","author":"MB Conde","year":"2009","unstructured":"Conde MB, Efron A, Loredo C, De Souza GR, Graca NP, Cezar MC, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet. 2009;373(9670):1183\u20139.","journal-title":"Lancet"},{"issue":"3","key":"565_CR29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1164\/rccm.200603-360OC","volume":"174","author":"WJ Burman","year":"2006","unstructured":"Burman WJ, Goldberg S, Johnson JL, Muzanye G, Eagle M, Mosher AW, et al. Moxifloxacin versus ethambutol in the first 2\u00a0months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006;174(3):331\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"565_CR30","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1128\/AAC.00105-15","volume":"59","author":"SY Li","year":"2015","unstructured":"Li SY, Irwin SM, Converse PJ, Mdluli KE, Lenaerts AJ, Nuermberger EL. Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models. Antimicrob Agents Chemother. 2015;59(7):4026\u201330.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"565_CR31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1473-3099(14)70885-0","volume":"15","author":"C Nimmo","year":"2015","unstructured":"Nimmo C, Lipman M, Phillips PP, McHugh T, Nunn A, Abubakar I. Shortening treatment of tuberculosis: lessons from fluoroquinolone trials. Lancet Infect Dis. 2015;15(2):141\u20133.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"565_CR32","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/cid\/civ911","volume":"62","author":"JP Lanoix","year":"2016","unstructured":"Lanoix JP, Chaisson RE, Nuermberger EL. Shortening tuberculosis treatment with fluoroquinolones: lost in translation? Clin Infect Dis. 2016;62(4):484\u201390.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"565_CR33","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1093\/infdis\/jis041","volume":"205","author":"PP Phillips","year":"2012","unstructured":"Phillips PP, Gillespie SH, Boeree M, Heinrich N, Aarnoutse R, McHugh T, et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis. 2012;205 Suppl 2:S250\u20137.","journal-title":"J Infect Dis."},{"issue":"6","key":"565_CR34","doi-asserted-by":"crossref","first-page":"626","DOI":"10.5588\/ijtld.14.0988","volume":"19","author":"GR Davies","year":"2015","unstructured":"Davies GR, Phillips PP, Jaki T. Adaptive clinical trials in tuberculosis: applications, challenges and solutions. Int J Tuberc Lung Dis. 2015;19(6):626\u201334.","journal-title":"Int J Tuberc Lung Dis"}],"updated-by":[{"DOI":"10.1186\/s12916-016-0585-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T00:00:00Z","timestamp":1456185600000}}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-016-0565-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T09:10:41Z","timestamp":1748769041000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1741-7015\/14\/19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,4]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["565"],"URL":"https:\/\/doi.org\/10.1186\/s12916-016-0565-y","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,4]]},"article-number":"19"}}